Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Inflammation
Published in: Inflammation 3/2015

01-06-2015

In Vitro Oxidation of Fibrinogen Promotes Functional Alterations and Formation of Advanced Oxidation Protein Products, an Inflammation Mediator

Authors: Vanessa Dorneles Torbitz, Guilherme Vargas Bochi, José Antônio Mainardi de Carvalho, Rodrigo de Almeida Vaucher, José Edson Paz da Silva, Rafael Noal Moresco

Published in: Inflammation | Issue 3/2015

Login to get access

Abstract

Fibrinogen (FB) is a soluble blood plasma protein and is a key molecule involved in coagulation. Oxidative modification of proteins, such as the formation of advanced oxidation protein products (AOPP), a heterogeneous family of protein compounds structurally modified and derived from oxidative stress, may be associated with the pathophysiology of a number of chronic inflammatory diseases. Therefore, the aim of this study was to determine whether the formation of this mediator of inflammation occurs from FB and whether its generation is associated with structural changes. Results of the present study suggest that the oxidation of FB may provoke the formation of AOPP, which in turn, may promote functional alterations in FB, thus causing changes in its structural domains and increasing its procoagulant activity.
Literature
1.
Liu, C.Y., H.L. Nossel, and K.L. Kaplan. 1979. The binding of thrombin by fibrin. The Journal of Biological Chemistry 254: 10421–10425.PubMed
2.
Collen, D., G. Tygat, H. Claeys, and R. Piessens. 1972. Metabolism and distribution of fibrinogen. I. Fibrinogen turnover in physiological conditions in humans. British Journal of Haematology 22: 681–700.CrossRefPubMed
3.
Brow, J.H., N. Volkmann, G. Jun, A.H. Henschen-Edman, and C. Cohen. 2000. The crystal structure of modified bovine fibrinogen. Proceedings of National Academy of Sciences of the United States of America 97: 85–90.CrossRef
4.
Hall, C.E., and H.S. Slayter. 1959. The fibrinogen molecule: its size, shape, and mode of polymerization. The Journal of the Biophysical and Biochemical Cytology 5: 11–16.CrossRef
5.
Kollman, J.M., L. Pandi, M.R. Sawaya, M. Riley, and R.F. Doolittle. 2009. Crystal structure of human fibrinogen. Biochemistry 48: 3877–3886.CrossRefPubMed
6.
Budzynski, A.Z., S.A. Olexa, and B.V. Pandya. 1983. Fibrin polymerization sites in fibrinogen and fibrin fragments. Annals of the New York Academy of Sciences 408: 301–314.CrossRefPubMed
7.
Martinez, M., J.W. Weisel, and H. Ischiropoulos. Functional impact of oxidative posttranslational modifications on fibrinogen and fibrin clots. 2013. Free Radical Biology and Medicine 65: 411-418.
8.
Dalle-Donne, I., R. Rossi, D. Giustarini, A. Milzani, and R. Colombo. 2003. Protein carbonyl groups as biomarkers of oxidative stress. Clinica Chimica Acta 329: 23–38.CrossRef
9.
Witko-Sarsat, V., M. Friedlander, C. Capeillère-Blandin, A.T. Nguyen-Khoa, A.T. Nguyen, J. Zingraff, P. Jungers, et al. 1996. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney International 49: 1304–1313.CrossRefPubMed
10.
Capeillere-Blandin, C., V. Gausson, B. Descamps-Latscha, and V. Witko-Sarsat. 2004. Biochemical and spectrophotometric significance of advanced oxidized protein products. Biochimica et Biophysica Acta 1689: 91–102.CrossRefPubMed
11.
Selmeci, L., M. Székely, P. Soós, L. Seres, N. Klinga, and A. Geiger. 2006. Human blood plasma advanced oxidation protein products (AOPP) correlates with fibrinogen levels. Free Radical Research 40: 952–958.CrossRefPubMed
12.
Bochi, G.V., V.D. Torbitz, L.P. Cargnin, M.B. Sangoi, R.C. Santos, P. Gomes, et al. 2012. Fructose-1,6-bisphosphate and N-acetylcysteine attenuate the formation of advanced oxidation protein products, a new class of inflammatory mediators, in vitro. Inflammation 35: 1786–1792.CrossRefPubMed
13.
Hanasand, M., R. Omdal, K.B. Norheim, L.G. Gøransson, C. Brede, and G. Jonsson. 2013. Improved detection of advanced oxidation protein products in plasma. Clinica Chimica Acta 413: 901–906.CrossRef
14.
Carr, Jr., and J. Hermans. 1978. Size and density of fibrin fibers from turbidity. Macromolecules 11: 46–50.CrossRefPubMed
15.
Laemmli, U.K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680–685.CrossRefPubMed
16.
Witko-Sarsat, V., V. Gausson, A.T. Nguyen, M. Touam, T. Drüeke, F. Santangelo, et al. 2003. AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylcysteine treatment in dialysis patients. Kidney International 64: 82–91.CrossRefPubMed
17.
Margret, C.M., and C.C. Winterbourn. 1991. Oxidative damage to fibrinonectin I. Effects of the Neutrophil myeloperoxidase system and HOCl. The Archieves of Biochemistry and Biophysics 15: 53–59.
18.
Weigandt, K.M., N. White, D. Chung, E. Ellingson, Y. Wang, and X. Fu. 2012. Fibrin clot structure and mechanics associated with specific oxidation of methionine residues in fibrinogen. Biophysical Journal 103: 2399–2407.CrossRefPubMedCentralPubMed
19.
Kannel, W.B., P.A. Wolf, W.P. Castelli, and R.B. D’Agostino. 1987. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 258: 1183–1186.CrossRefPubMed
20.
Stec, J.J., H. Silbershatz, G.H. Tofler, T.H. Matheney, P. Sutherland, I. Lipinska, et al. 2000. Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population. Circulation 102: 1634–1638.CrossRefPubMed
21.
Upchurch Jr., G.R., N. Ramdev, M.T. Walsh, and J. Loscalzo. 1998. Prothrombotic consequences of the oxidation of fibrinogen and their inhibition by aspirin. Journal of Thrombosis and Thrombolysis 5: 9–14.CrossRef
22.
Belisario, M.A., C. Di Domenico, A. Pelagalli, R. Della Morte, and N. Staiano. 1997. Metal-ion catalyzed oxidation affects fibrinogen activity on platelet aggregation and adhesion. Biochimie 79: 449–455.CrossRefPubMed
Metadata
Title
In Vitro Oxidation of Fibrinogen Promotes Functional Alterations and Formation of Advanced Oxidation Protein Products, an Inflammation Mediator
Authors
Vanessa Dorneles Torbitz
Guilherme Vargas Bochi
José Antônio Mainardi de Carvalho
Rodrigo de Almeida Vaucher
José Edson Paz da Silva
Rafael Noal Moresco
Publication date
01-06-2015
Publisher
Springer US
Published in
Inflammation / Issue 3/2015
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-014-0085-x

Other articles of this Issue 3/2015

Inflammation 3/2015 Go to the issue

OriginalPaper

Preventive Effects of Protocatechuic Acid on LPS-Induced Inflammatory Response in Human Gingival Fibroblasts via Activating PPAR-γ

OriginalPaper

Inflammatory Stress Exacerbated Mesangial Foam Cell Formation and Renal Injury via Disrupting Cellular Cholesterol Homeostasis

OriginalPaper

Intranasal Curcumin Ameliorates Lipopolysaccharide-Induced Acute Lung Injury in Mice

Erratum

Erratum to: Potential Effects of Calcium Binding Protein S100A12 on Severity Evaluation and Curative Effect of Severe Acute Pancreatitis

OriginalPaper

Additive Suppression of LPS-Induced IL-10 and TNF-α by Pre-treatment of Dexamethasone and SB203580 in a Murine Alveolar Macrophage Cell Line (MH-S)

OriginalPaper

Inhibitory Effects of JEUD-38, a New Sesquiterpene Lactone from Inula japonica Thunb, on LPS-Induced iNOS Expression in RAW264.7 Cells
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits